Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Real Time Price. Currency in USD
51.55-0.08 (-0.15%)
As of 2:38 PM EDT. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close51.63
Bid51.68 x 400
Ask51.69 x 500
Day's Range51.13 - 52.29
52wk Range48.01 - 66.55
1y Target EstN/A
Market Cap47.12B
P/E Ratio (ttm)34.44
Avg Vol (3m)5,648,640
Dividend & Yield1.36 (2.56%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Barrons.com1 hour ago

    Specialty Pharma: Never Mind the Pricing Controversy, Fundamentals Will Win Out

    While fundamentals of the group appear stable following the recent 2Q16 earnings season (see our recent note here) and valuations are attractive, we acknowledge that ongoing negative headlines may stunt the fledgling “recovery” that has started to take place in the space over the past couple of months. More broadly, while media scrutiny/political headlines around drug pricing could result in continued volatility through the elections, we continue to see the group positioned for a recovery over time, with valuations inexpensive on almost any metric (~8x 2017 EPS) and improving fundamentals after a challenging 1H/16.

  • MarketWatch1 hour ago

    After Mylan uproar, a generic EpiPen could hit the market in 2017

    Mylan’s EpiPen monopoly could end in 2017 as the Food and Drug Administration may speed up approval of a generic competitor.

  • Why Mylan's EpiPen Is Sparking "Epi-Rage"
    Motley Fool4 hours ago

    Why Mylan's EpiPen Is Sparking "Epi-Rage"

    A series of price increases have patients and advocates up in arms.